- Molecular NameChlorothiazide
- SynonymChlorothiazid; Chlorthiazide; Chlortiazid
- Weight295.727
- Drugbank_IDDB00880
- ACS_NO58-94-6
- Show 3D model
- LogP (experiment)-0.24
- LogP (predicted, AB/LogP v2.0)-0.08
- pka6.7, 9.5
- LogD (pH=7, predicted)-0.55
- Solubility (experiment)0.266 mg/ml
- LogS (predicted, ACD/Labs)(ph=7)-2.34
- LogSw (predicted, AB/LogsW2.0)0.76
- Sw (mg/ml) (predicted, ACD/Labs)0.16
- No.of HBond Donors3
- No.of HBond Acceptors7
- No.of Rotatable Bonds1
- TPSA135.45
- StatusFDA approved
- AdministrationN/A
- PharmacologyA diuretic used within the hospital setting or for personal use to manage excess fluid associated with congestive heart failure. It is also used as an antihypertensive.
- Absorption_value60.0
- Absorption (description)Poorly and erratically absorbed after oral administration; bioavailability, about 20 to 30% after doses of 250 mg, decreasing with increasing dose.
- Caco_2N/A
- Bioavailability13.0
- Protein binding95.0
- Volume of distribution (VD)N/A
- Blood/Plasma Partitioning ratio (D_blood)N/A
- MetabollsmChlorothiazide is not significantly metabolised
- Half life1.5 h
- ExcretionExcreted in the urine to a variable extent depending on the extent of absorption.
- Urinary ExcretionN/A
- CleranceN/A
- ToxicitySigns of overdose include those caused by electrolyte depletion (hypokalemia, hypochloremia, hyponatremia) and dehydration resulting from excessive diuresis. If digitalis has also been administered hypokalemia may accentuate cardiac arrhythmias.
- LD50 (rat)rat LD50: > 10 g/kg
- LD50 (mouse)LD50=618 (intraperitoneal administration)